Patients
Patient Support ProgramPatient Stories
How Altius Works
Healthcare Providers
The Altius® SystemClinical ResultsClinical LiteratureInstructions for Use
FAQ
See if you qualify

News

Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints

ALISO VIEJO, California, June 6, 2022/PRNewswire/ — Neuros Medical, Inc., a medical device company developing an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, announced today the completion of its QUEST Pivotal Trial 90-day primary endpoints. QUEST outcomes will remain blinded through the 12-month follow-up period, per protocol.

QUEST is a 180-subject randomized, double blinded, active sham controlled clinical trial that is being conducted under an Investigational Device Exemption (IDE). QUEST is designed to assess the safety & effectiveness of the Company’s Altius® Bioelectric Nerve Block Technology to treat intractable post-amputation pain. Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

The Company continues its plans for expansion of its facility and future headquarters in Aliso Viejo, CA. The 10,000 square foot operation was recently certified by the designated European Notified Body, BSI, to International Standards Organization (ISO) 13485:2016.

“Expansion and ISO certification of our California headquarters will enable us to add additional personnel as we prepare to submit the Altius System Pre-Market Approval application after the QUEST study is unblinded in the Fall of 2022,” said William R. Patterson, PhD, Chief Technology Officer.

About Neuros Medical, Inc.

Neuros Medical, a bioelectric technology company, has developed the Altius system for the treatment of chronic post-amputation pain (Phantom Limb Pain and Residual Limb Pain). Altius incorporates the Company’s patented platform technology, On-Demand Bioelectric Nerve Block. Patients initiate a 30-minute Altius treatment session as needed for targeted pain relief.

Neuros’ technology delivers a bioelectric signal to sensory nerves in the peripheral nervous system to block the pain signal. The system consists of a nerve cuff electrode (also known as a lead) placed around a peripheral nerve and an implantable pulse generator (IPG).

Chronic pain is characterized as pain lasting more than 3 months in duration. Post-amputation pain includes both phantom limb and residual limb (or “stump”) pain, and impacts nearly one million Americans. There are nearly two million amputees in the U.S., with 185,000 new amputations occurring every year. Post-amputation pain represents a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.

For more information, please visit www.neurosmedical.com.  Additional information regarding the QUEST IDE study can be found at https://clinicaltrials.gov/ct2/show/NCT02221934. The Altius is an investigational device that is not available for sale in the United States.

For additional information regarding Neuros Medical, please contact:

Amy Smith, VP Global Marketing
asmith@neurosmedical.com
www.neurosmedical.com
(440) 951-2565, Ext. 127

‍

More Altius News

View All News

Neuros Medical Announces CMS Final Rule Granting Medicare Transitional Pass-Through Status for the ALTIUS® System in 2027 Calendar Year Rulemaking

November 5, 2026

Neuros Medical Announces First Commercial Implant of the Altius® Direct Electrical Nerve Stimulation System, a Breakthrough Non-Opioid Treatment for Chronic Post-Amputation Pain

July 23, 2025

Neuros Medical Secures $56M Series D to Commercialize the Altius® System, an FDA-Approved, Non-Opioid Nerve Stimulation System for Chronic Post-Amputation Pain

July 14, 2025

Important safety information

This information is for informational purposes only, is not medical advice or a diagnosis, and is not a substitute for professional medical advice. Consult with your healthcare provider regarding your condition. Individual symptoms, circumstances, and results vary.

Indications for use

The Altius® Direct Electrical Nerve Stimulation System is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees.

Contraindications

The Altius System is contraindicated for patients who are: Unable to operate the system or Unsuitable for the Altius implant surgery.

Warnings/Precautions

Use as indicated and instructed. Diathermy should not be used on patients with the Altius System, or any of its components, either as a treatment for a medical condition or as part of a surgical procedure. Electromagnetic interference (EMI) is a field of energy generated by equipment found in the home, work, medical, or public environments that is strong enough to interfere with Altius System function. The electrical pulses from the Altius System may interact with the sensing operation from a cardiac device and could result in an inappropriate response of the cardiac device; physicians involved should discuss the possible interactions between the devices before surgery. Safety and effectiveness of the Altius System for pediatric use and for pregnant patients has not been established. Surgical complications and adverse events may be more frequent and severe in diabetic patients. Safety of MRI/NMRI with an implanted Altius System has not been evaluated. Patients implanted with the Altius System, or any of its components, should not be subject to MRI/NMRI. See Instructions for Use for detailed information regarding the procedure(s), indications, contraindications, warnings, precautions, and potential adverse events before performing the Altius procedure. For more information and to view full Instructions for Use, visit www.neurosmedical.com.

Although FDA has determined that the probable benefits outweigh the probable risks, there remains some uncertainty regarding the manufacturer’s human factors engineering (HFE) and usability engineering (UE) analysis and validation testing. As a condition of approval, FDA is requiring the manufacturer to provide an HFE/UE analysis and validation testing and recommending that this analysis and testing is designed using the FDA’s 2016 guidance document “Applying Human Factors and Usability Engineering to Medical Devices” (https://www.fda.gov/media/80481/download).

Rx Only.

Patients
How Altius® WorksPatient Support ProgramPatient StoriesFAQContactUnderstanding Phantom Limb Pain
Healthcare Providers
The Altius® SystemClinical ResultsClinical LiteratureInstructions for UseGet in Touch
About & Contact
About UsCertificationNewsEmployment

1212 Red Fox Rd
Arden Hills, MN 55112

Phone: (440) 951-2565
© Neuros Medical Inc 2026 | All rights reserved.
Privacy PolicyTerms of ServiceCookie PolicyConsent Preferences
Rx Only
LB-0216 Rev P